Immunovant (IMVT) risk factors, FY2026 10-K

Risks Related to Development, Regulatory Approval and Commercialization

1. 01Our business is dependent on the successful and timely development, regulatory approval and commercialization of our product candidates
2. 02Clinical trials are very expensive, time-consuming, difficult to design and implement, and involve uncertain outcomes
3. 03Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control and we may not be able to enroll patients in our trials on our anticipated timelines
4. 04The results of our preclinical studies and clinical trials may not support our proposed claims for our product candidates, or regulatory approval on a timely basis or at all, and the results of earlier studies and trials may not be predictive of future trial results54% rewritten
5. 05Interim, “top-line” or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
6. 06Our product candidates are antibody proteins that could cause an immune response in patients, resulting in the creation of harmful or neutralizing antibodies against these therapeutic proteins, preventing or limiting regulatory approval or our ability to commercialize our product candidates
7. 07If we are not able to obtain required regulatory approvals, we will not be able to commercialize IMVT-1402 or any future product candidate, and our ability to generate product revenue will be impaired
8. 08We face significant competition from other biotechnology and pharmaceutical companies targeting autoimmune disease indications. Our operating results will suffer if we fail to compete effectively52% rewritten
9. 09IMVT-1402 may also face competition in CIDP from agents in Phase 3 development with different mechanisms of action including C1 inhibitors riliprubart (Sanofi), DNTH103 (Dianthus) and C2 inhibitor empasiprubart (Argenx SE)48% rewritten
10. 10Additional time may be required to obtain marketing authorizations for the autoinjector presentation of IMVT-1402 because it would be subject to regulation as a combination product
11. 11Even if we obtain regulatory approval for a product candidate, we will still face extensive ongoing quality and regulatory compliance requirements and our product may face future development and quality or regulatory compliance difficulties
12. 12Even if we receive marketing approval for any product candidate, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success
13. 13We may expend our limited resources to pursue particular indications and fail to capitalize on indications that may be more profitable or for which there is a greater likelihood of success
14. 14If we are unable to establish sales, marketing and distribution capabilities, either on our own, or in collaboration with third parties, we may not be successful in commercializing our product candidates, if approved71% rewritten
15. 15We may seek orphan drug designations for IMVT-1402 or other product candidates we develop, but we may be unable to obtain such further designation or to maintain the benefits associated with orphan drug status even if that designation is grantedNew
16. 16If we obtain approval to commercialize our product or any future product candidate outside of the U.S., a variety of risks associated with international operations could adversely affect our business
17. 17Our current and future relationships with investigators, healthcare professionals, consultants, third-party payors and customers are subject to applicable healthcare regulatory laws, which could expose us to penalties or other negative actions49% rewritten
18. 18Legislation targeting biotechnology companies with ties to certain foreign adversaries, including the BIOSECURE Act, could materially adversely affect our business, supply chain and results of operationsNew
19. 19Changes in healthcare law and implementing regulations, as well as changes in healthcare policy, may impact our business in ways that we cannot currently predict and may have a significant adverse effect on our business and results of operations53% rewritten
20. 20Coverage and adequate reimbursement may not be available for our product candidates, which could make it difficult for us to sell it profitably, if approved39% rewritten

Risks Related to Our Business, Financial Position and Capital Requirements

1. 21We expect to incur significant losses for the foreseeable future and may never achieve or maintain profitability29% rewritten
2. 22We have a limited operating history and have never generated any product revenue
3. 23Even if we receive regulatory approval for IMVT-1402 or any future product candidate, we do not know when or if we will generate product revenue
4. 24We may not be successful in our efforts to identify and acquire or in-license additional product candidates or technologies or to enter into collaborations or strategic alliances for the development and commercialization of any such future product candidates
5. 25We will require additional capital to fund our operations. If we fail to obtain necessary financing, we may not be able to complete the development and commercialization of our product candidates28% rewritten
6. 26Raising additional funds by issuing equity securities will cause dilution to existing stockholders. Raising additional funds through debt financings may involve restrictive covenants and raising funds through lending and licensing arrangements may restrict our operations or require us to relinquish proprietary rights
7. 27We rely on the HanAll Agreement to provide us rights to the core intellectual property relating to IMVT-1402 and batoclimab. Any termination or loss of significant rights under the HanAll Agreement could adversely affect our development or commercialization of IMVT-140291% rewritten
8. 28The HanAll Agreement obligates us to make milestone payments, some of which may be triggered prior to our potential commercialization of any product candidate86% rewritten
9. 29We may not be able to attract or retain qualified management, scientific, clinical and commercial personnel due to the intense competition for qualified individuals among biotechnology, pharmaceutical and other businessesNew
10. 30International expansion of our business exposes us to business, legal, regulatory, political, operational, financial and economic risks associated with conducting business outside of the U.S
11. 31Any of these risks, if encountered, could significantly harm our future international expansion and operations and consequently, negatively impact our financial condition and results of operations
12. 32In the ordinary course of our business, we Process proprietary, confidential and sensitive information, including personal information (including health information), intellectual property, trade secrets and proprietary business information owned or controlled by ourselves or other parties (“Sensitive Information”)
13. 33Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop67% rewritten
14. 34The biopharmaceutical industry is subject to extensive regulatory obligations and policies that may be subject to significant and abrupt change, including due to judicial challenges, election cycles, and resulting regulatory updates and changes in policy prioritiesNew
15. 35Any resulting changes in regulation may result in unexpected delays, increased costs, or other negative impacts on our business that are difficult to predictNew

Risks Related to Our Dependence on Third Parties

1. 36A portion of our manufacturing, clinical trial activities and laboratory research takes place in Asia. A significant disruption in that region, such as a trade war or political unrest, or adverse legislation could materially adversely affect our business, financial condition and results of operations
2. 37We rely on third parties to conduct, supervise and monitor our clinical trials and if those third parties perform in an unsatisfactory manner or fail to comply with applicable requirements or our quality management program fails to detect such events in a timely manner, it may harm our business

Risks Related to Our Intellectual Property

1. 38Our product candidates for which we intend to seek approval as a biological product may face competition sooner than anticipated
2. 39The validity, scope and enforceability of any patents that cover a biologic subject to approval by the FDA via a BLA, such as IMVT-1402 or batoclimab, can be challenged by third parties
3. 40If we are unable to obtain and maintain patent protection for IMVT-1402, batoclimab, or any future product candidates or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets
4. 41We may not be able to protect or enforce our intellectual property rights throughout the world
5. 42Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time
6. 43If we are not able to obtain patent term extension in the U.S. under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of our marketing exclusivity for batoclimab, IMVT-1402 or other product candidates that we may identify, our business may be harmed
7. 44We do not have rights to protect intellectual property in certain territories and may be unable to adequately protect our rights
8. 45If we fail to comply with our obligations under any license, collaboration or other agreements, including the HanAll Agreement, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our product candidates73% rewritten
9. 46Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies and our patent protection could be reduced or eliminated for noncompliance with these requirements
10. 47We may not be successful in obtaining necessary intellectual property rights to future products through acquisitions and in-licenses
11. 48We may need to license intellectual property from third parties and such licenses may not be available or may not be available on commercially reasonable terms
12. 49Third-party claims or litigation alleging infringement of patents or other proprietary rights or us seeking to invalidate patents or other proprietary rights may delay or prevent the development and commercialization of our product candidates
13. 50We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our product candidates or any future product candidates
14. 51We may become involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property rights, which could be expensive, time-consuming and unsuccessful
15. 52Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties
16. 53Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect batoclimab, IMVT-1402 or any of our future product candidates
17. 54If we are unable to protect the confidentiality of our trade secrets and other proprietary information, including as a result of our reliance on third parties, our business and competitive position could be harmed
18. 55We may be subject to claims that our licensors, employees, consultants, independent contractors or we have wrongfully used or disclosed confidential information of their former employers or other third parties
19. 56We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property
20. 57Any trademarks and trade names we have obtained or may obtain may be infringed or successfully challenged, resulting in harm to our business
21. 58Intellectual property rights do not necessarily address all potential threats to our competitive advantage
22. 59RSL owns a significant percentage of shares of our common stock and may exert significant control over matters subject to stockholder approval
23. 60RSL has the right to elect a certain number of directors to our board of directors
24. 61Our organizational and ownership structure may create significant conflicts of interests
25. 62The market price of shares of our common stock has been and is likely to be highly volatile, and you may lose some or all of your investment
26. 63We have been and could be subject to securities litigation, which is expensive and could divert management attention and adversely impact our business
27. 64If securities or industry analysts do not publish research or reports about our business or publish negative reports about our business, our share price and trading volume could decline and has declined in the past upon downgrades of our common stock
28. 65Because we do not anticipate paying any cash dividends on shares of our common stock in the foreseeable future, capital appreciation, if any, would be your sole source of gain
29. 66As a public company, we are obligated to develop and maintain proper and effective internal controls over financial reporting and any failure to maintain the adequacy of these internal controls may adversely affect investor confidence in our company and, as a result, the value of shares of our common stock
30. 67We may become subject to unanticipated tax liabilities and higher effective tax rates43% rewritten
31. 68Our intercompany arrangements depend on the application of the tax laws of various jurisdictions and on how we operate our business33% rewritten
32. 69Changes in tax laws or our effective tax rate may reduce our net income in future periods
33. 70Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of our company more difficult, limit attempts by our stockholders to replace or remove our current management and limit the market price of our common stock